500 shock patients tracked to unlock better heart care
NCT ID NCT05185492
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 500 people with cardiogenic shock, a life-threatening condition where the heart suddenly can't pump enough blood. Researchers will collect data from four specialized centers to understand what treatments work best and why some patients do better than others. No new drug or device is being tested; instead, the goal is to learn from real-world care to improve survival and reduce complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 500 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2022
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients presenting with cardiogenic shock at one of four high-volume North American quaternary care centers (Inova Heart and Vascular Institute, Sentara Norfolk General Hospital, University of Toronto and University of Utah)
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Primary diagnosis of cardiogenic shock at time of index evaluation; including acute myocardial infarction- and acute decompensated heart failure-cardiogenic shock phenotypes * Patients with cardiac arrest complicating cardiogenic shock and those with massive pulmonary embolism with right ventricular cardiogenic shock will also be eligible for the registry Exclusion Criteria: * Patients with shock not due to primary cardiac etiology will be excluded. These include septic, hemorrhagic, and anaphylactic shock.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute decompensated heart failure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites in 2 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Cleveland Clinic Florida
RECRUITINGWeston, Florida, 33331, United States
-
Inova Heart and Vascular Institute
RECRUITINGFalls Church, Virginia, 22042, United States
-
University of Toronto
RECRUITINGToronto, Ontario, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Every minute counts: study tracks how delays shape heart attack survival
- Stick-On patch aims to catch dangerous heart decline sooner
- Heart pump timing put to the test in deadly heart attack shock
- A second chance for the heart: can rehab rewrite the story after shock?
- Blood filter may calm the deadly inflammation of cardiogenic shock
- Microscopic blood vessel health may hold key to cardiogenic shock survival